Objective: To evaluate the respective contributions of short-term glycemic variability and mean daily glucose (MDG) concentration to the risk of hypoglycemia in type 1 diabetes.
Research Design And Methods: People with type 1 diabetes ( = 100) investigated at the University Hospital of Montpellier (France) underwent continuous glucose monitoring (CGM) on two consecutive days, providing a total of 200 24-h glycemic profiles. The following parameters were computed: MDG concentration, within-day glycemic variability (coefficient of variation for glucose [%CV]), and risk of hypoglycemia (presented as the percentage of time spent below three glycemic thresholds: 3.9, 3.45, and 3.0 mmol/L).
Results: MDG was significantly higher, and %CV significantly lower (both < 0.001), when comparing the 24-h glycemic profiles according to whether no time or a certain duration of time was spent below the thresholds. Univariate regression analyses showed that MDG and %CV were the two explanatory variables that entered the model with the outcome variable (time spent below the thresholds). The classification and regression tree procedure indicated that the predominant predictor for hypoglycemia was %CV when the threshold was 3.0 mmol/L. In people with mean glucose ≤7.8 mmol/L, the time spent below 3.0 mmol/L was shortest ( < 0.001) when %CV was below 34%.
Conclusions: In type 1 diabetes, short-term glycemic variability relative to mean glucose (i.e., %CV) explains more hypoglycemia than does mean glucose alone when the glucose threshold is 3.0 mmol/L. Minimizing the risk of hypoglycemia requires a %CV below 34%.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2337/dc19-1549 | DOI Listing |
Int Ophthalmol Clin
January 2025
Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX.
Aim: Determine the follow-up rate for patients referred following an abnormal teleretinal imaging (TRI) screening and examine patient characteristics predictive of follow-up nonadherence.
Materials And Methods: A cross-sectional study of patients screened between August 2014 and July 2016 in the Harris Health System (HHS) in Houston, TX. All diabetic patients referred for in-person examination, who had data for all study variables, and who did not have established ophthalmic care in the HHS within the previous 2 years were included.
BMC Geriatr
December 2024
Geriatric Endocrinology, Department of Geriatric Endocrinology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Shushan District, Hefei City, Anhui Province, China.
J Diabetes Sci Technol
December 2024
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
Background: Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells, leading to lifelong insulin dependence. Despite advancements in insulin therapies and glucose monitoring, maintaining optimal blood glucose control remains challenging with common issues like weight gain and glucose variability. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), approved for type 2 diabetes and obesity, are being explored off-label for T1D.
View Article and Find Full Text PDFInt J Med Inform
December 2024
Department of Health Science and Technology, Aalborg University, Aalborg, Denmark; Data Science, Novo Nordisk A/S, Søborg, Denmark. Electronic address:
Introduction: Optimal basal insulin titration for people with type 2 diabetes is vital to effectively reducing the risk of complications. However, a sizeable proportion of people (30-50 %) remain in suboptimal glycemic control six months post-initiation of basal insulin. This indicates a clear need for novel titration methods that account for individual patient variability in real-world settings.
View Article and Find Full Text PDFLancet Diabetes Endocrinol
December 2024
German Center for Diabetes Research (DZD), Neuherberg, Germany; Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany.
Background: The effect of closed-loop insulin delivery on the risk of acute diabetes complications in people with type 1 diabetes is unclear. We investigated whether the rates of severe hypoglycaemia and diabetic ketoacidosis are lower with hybrid closed-loop insulin therapy compared with sensor-augmented (open-loop) pump therapy in a large cohort of young people.
Methods: In this population-based cohort study, we evaluated young people with type 1 diabetes from 250 diabetes centres in Germany, Austria, Switzerland, and Luxembourg participating in the Diabetes Prospective Follow-up (DPV) initiative.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!